TelyRx appoints Benjamin Atkins as interim CEO
TelyRx Holdings (TELY) appointed Benjamin Atkins as interim CEO and President, effective November 12, 2026, following Vanessa Slowey's resignation. Atkins, a co-founder and board member, brings industry experience. The board is searching for a permanent replacement. TELYF shares fell 11.43%.
How this was made

The 30-second read
Why it matters
The change may affect stock volatility and could prompt short sellers to target the ticker.
Market read
Executive turnover at a micro‑cap biotech, modest trading relevance.
What to watch
Potential undisclosed strategic plans or financing actions tied to the leadership change.
Background
TelyRx Holdings Inc. is a small biotech focused on healthcare access; the appointment follows the founder's departure.
Ticker impact
TelyRx appointed co‑founder Benjamin Atkins as interim CEO and President, replacing Vanessa Slowey.
likely modest downside as investors assess interim management.
Executive changes at micro‑caps often trigger sell pressure until strategic direction is clarified.
Market effects
Minimal impact on broader healthcare sector; only relevant to niche biotech investors.
No discernible regional effect.
Limited to investors tracking small‑cap biotech news.
Counterpoint
The interim CEO could accelerate upcoming initiatives, offering a short‑term upside opportunity.
Key entities
- personBenjamin Atkins
Co‑founder and board member, now interim CEO.
- personVanessa Slowey
Outgoing CEO stepping down.



